http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 20:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++3++++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Oct+13++Filed+by%3A+Farrow+Jeffrey+S/27194529.html si-local-file:///var/storage/secattach/20261015/27194529.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Oct+13++Filed+by%3A+Farrow+Jeffrey+S/27194529.html Thu, 15 Oct 2026 20:45:00 -0400 LSTA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Oct+13/27187417.html si-local-file:///var/storage/secattach/20261014/27187417.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Oct+13/27187417.html Wed, 14 Oct 2026 16:26:00 -0400 LSTA http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html <p>Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced the appointment of Jeffrey Farrow to its board of directors, effective October 13, 2026, expanding the board from seven to eight members.</p> <p>Farrow fills a newly created Class III director seat, appointed upon the recommendation of the Nominating and Corporate Governance Committee. He will also serve on the Audit Committee. The board has determined that Farrow qualifies as independent under Nasdaq listing rules.</p> <p>Farrow currently serves as Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS). He also sits on the boards of Clover Biopharmaceuticals, Ltd. (HKEX) and Achieve Life Sciences, Inc. http://www.streetinsider.com/Board+Changes/Lisata+Therapeutics+adds+Jeffrey+Farrow+to+its+board+of+directors/27187130.html Wed, 14 Oct 2026 16:05:23 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html <p><strong>Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee</strong></p><p>LIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”) today announced the appointment of Jeffrey Farrow to its Board of Directors, effective October 13, 2026.</p> <p>Mr. Farrow fills a newly created seat, expanding the Board from seven to eight members. He was appointed as a Class III director upon the recommendation of the Nominating and Corporate Governance Committee and will also serve on the Audit Committee. The Board http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Appoints+Jeff+Farrow+to+Board+of+Directors/27187100.html Wed, 14 Oct 2026 16:05:00 -0400 ACHV LSTA TARS http://www.streetinsider.com/Corporate+News/Lisata+gets+new+patent+for+certepetide+in+pancreatic+cancer+treatment/27164072.html <p>Lisata Therapeutics, Inc. (NASDAQ: LSTA) announced that the United States Patent and Trademark Office has granted a new method of use patent for its drug candidate certepetide, covering its use in treating pancreatic cancer and other solid tumors.</p><p>The patent, U.S. Patent No. 12,751,991, is titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors" and expires in May 2041. It covers administering certepetide in combination with at least one anti-cancer agent or therapy to treat pancreatic cancer and other solid tumors, including metastatic, refractory, and drug-resistant cancers.</p><p>David J. Mazzo, Ph.D., chief executive officer of Lisata, said the patent "secures important http://www.streetinsider.com/Corporate+News/Lisata+gets+new+patent+for+certepetide+in+pancreatic+cancer+treatment/27164072.html Thu, 08 Oct 2026 08:04:50 -0400 LSTA http://www.streetinsider.com/Hot+Corp.+News/Lisata+gets+new+patent+for+certepetide+in+pancreatic+cancer+treatment/27164072.html <p>Lisata Therapeutics, Inc. (NASDAQ: LSTA) announced that the United States Patent and Trademark Office has granted a new method of use patent for its drug candidate certepetide, covering its use in treating pancreatic cancer and other solid tumors.</p><p>The patent, U.S. Patent No. 12,751,991, is titled "Methods for Treating Pancreatic Cancer and Other Solid Tumors" and expires in May 2041. It covers administering certepetide in combination with at least one anti-cancer agent or therapy to treat pancreatic cancer and other solid tumors, including metastatic, refractory, and drug-resistant cancers.</p><p>David J. Mazzo, Ph.D., chief executive officer of Lisata, said the patent "secures important http://www.streetinsider.com/Hot+Corp.+News/Lisata+gets+new+patent+for+certepetide+in+pancreatic+cancer+treatment/27164072.html Thu, 08 Oct 2026 08:04:50 -0400 LSTA http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Announces+New+Method+of+Use+Patent+Granted+for+Certepetide+in+the+Treatment+of+Pancreatic+Cancer+and+Other+Solid+Tumors/27163840.html <p>LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.</p> <p>The newly issued patent, titled “<em>Methods for Treating Pancreatic Cancer and Other Solid Tumors</em>,” expands Lisata’s intellectual property protection for certepetide. The patent covers administering the Company’s proprietary cyclic peptide in combination with at least one anti-cancer http://www.streetinsider.com/Press+Releases/Lisata+Therapeutics+Announces+New+Method+of+Use+Patent+Granted+for+Certepetide+in+the+Treatment+of+Pancreatic+Cancer+and+Other+Solid+Tumors/27163840.html Thu, 08 Oct 2026 08:00:00 -0400 LSTA http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Announces+New+Method+of+Use+Patent+Granted+for+Certepetide+in+the+Treatment+of+Pancreatic+Cancer+and+Other+Solid+Tumors/27163840.html <p>LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.</p> <p>The newly issued patent, titled “<em>Methods for Treating Pancreatic Cancer and Other Solid Tumors</em>,” expands Lisata’s intellectual property protection for certepetide. The patent covers administering the Company’s proprietary cyclic peptide in combination with at least one anti-cancer http://www.streetinsider.com/Globe+Newswire/Lisata+Therapeutics+Announces+New+Method+of+Use+Patent+Granted+for+Certepetide+in+the+Treatment+of+Pancreatic+Cancer+and+Other+Solid+Tumors/27163840.html Thu, 08 Oct 2026 08:00:00 -0400 LSTA http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++LISATA+THERAPEUTICS%2C++++++For%3A+Nov+09/27161999.html si-local-file:///var/storage/secattach/20261007/27161999.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14A++++LISATA+THERAPEUTICS%2C++++++For%3A+Nov+09/27161999.html Wed, 07 Oct 2026 17:17:00 -0400 LSTA http://www.streetinsider.com/FDA/Marea+Therapeutics+doses+first+patient+in+phase+2+acromegaly+trial/27145937.html <p>Marea Therapeutics, a subsidiary of Lisata Therapeutics (Nasdaq: LSTA), announced that the first patient has been dosed in a Phase 2 clinical trial of MAR002, an investigational therapy for the treatment of acromegaly.</p> <p>Acromegaly is a rare, chronic endocrine disorder caused by excess growth hormone secretion, typically from a benign pituitary adenoma, resulting in elevated insulin-like growth factor-1 (IGF-1). The condition affects approximately 30,000 patients in the U.S. and, if untreated, can shorten median lifespan by 10 years.</p> <p>MAR002 is described as a first-in-class allosteric monoclonal antibody targeting the growth hormone receptor. Phase 1 data presented at the Endocrine Society's annual meeting http://www.streetinsider.com/FDA/Marea+Therapeutics+doses+first+patient+in+phase+2+acromegaly+trial/27145937.html Mon, 05 Oct 2026 08:00:41 -0400 LSTA http://www.streetinsider.com/Press+Releases/Marea+Therapeutics%2C+a+Subsidiary+of+Lisata+Therapeutics%2C+Announces+First+Patient+Dosed+in+Phase+2+Clinical+Trial+of+MAR002%2C+a+Potential+Best-in-disease+Investigational+Therapy+for+the+Treatment+of+Acr/27145817.html <p align="center"><em>Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care</em></p> <p align="center"><em>By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients</em></p> <p>SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, LLC (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: http://www.streetinsider.com/Press+Releases/Marea+Therapeutics%2C+a+Subsidiary+of+Lisata+Therapeutics%2C+Announces+First+Patient+Dosed+in+Phase+2+Clinical+Trial+of+MAR002%2C+a+Potential+Best-in-disease+Investigational+Therapy+for+the+Treatment+of+Acr/27145817.html Mon, 05 Oct 2026 08:00:00 -0400 LSTA http://www.streetinsider.com/Globe+Newswire/Marea+Therapeutics%2C+a+Subsidiary+of+Lisata+Therapeutics%2C+Announces+First+Patient+Dosed+in+Phase+2+Clinical+Trial+of+MAR002%2C+a+Potential+Best-in-disease+Investigational+Therapy+for+the+Treatment+of+Acr/27145817.html <p align="center"><em>Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care</em></p> <p align="center"><em>By directly blocking growth hormone signaling at the receptor level, MAR002 has the potential to deliver meaningful biochemical control for a broad population of acromegaly patients</em></p> <p>SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, LLC (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: http://www.streetinsider.com/Globe+Newswire/Marea+Therapeutics%2C+a+Subsidiary+of+Lisata+Therapeutics%2C+Announces+First+Patient+Dosed+in+Phase+2+Clinical+Trial+of+MAR002%2C+a+Potential+Best-in-disease+Investigational+Therapy+for+the+Treatment+of+Acr/27145817.html Mon, 05 Oct 2026 08:00:00 -0400 LSTA http://www.streetinsider.com/SEC+Filings/Form++D++++++++++LISATA+THERAPEUTICS%2C+++++++++++++++++/27142649.html si-local-file:///var/storage/secattach/20261002/27142649.html http://www.streetinsider.com/SEC+Filings/Form++D++++++++++LISATA+THERAPEUTICS%2C+++++++++++++++++/27142649.html Fri, 02 Oct 2026 16:24:00 -0400 LSTA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Sep+17++Filed+by%3A+LOVE+TED+W/27115928.html si-local-file:///var/storage/secattach/20260928/27115928.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Sep+17++Filed+by%3A+LOVE+TED+W/27115928.html Mon, 28 Sep 2026 21:31:00 -0400 LSTA http://www.streetinsider.com/SEC+Filings/Form++3++++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Sep+17++Filed+by%3A+Lehrer-Graiwer+Joshua/27115926.html si-local-file:///var/storage/secattach/20260928/27115926.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++LISATA+THERAPEUTICS%2C++++++For%3A+Sep+17++Filed+by%3A+Lehrer-Graiwer+Joshua/27115926.html Mon, 28 Sep 2026 21:30:00 -0400 LSTA http://www.streetinsider.com/Corporate+News/Marea+Therapeutics+to+present+MAR001+trial+data+at+AHA+2026/27099157.html <p>Marea Therapeutics, a subsidiary of Lisata Therapeutics (Nasdaq: LSTA), announced that Phase 2b clinical data from its TYDAL study of MAR001 will be presented at the American Heart Association Scientific Sessions 2026, scheduled for November 6–9, 2026, in Chicago, Illinois.</p><p>The presentation, titled "TYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations," is scheduled for Monday, November 9, 2026, at 8:00 a.m. CT, in the late-breaking science session focused on cardiometabolic risk reduction.</p><p>MAR001 is a monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), a protein expressed in adipose tissue. The drug is http://www.streetinsider.com/Corporate+News/Marea+Therapeutics+to+present+MAR001+trial+data+at+AHA+2026/27099157.html Thu, 24 Sep 2026 08:04:08 -0400 LSTA http://www.streetinsider.com/FDA/Marea+Therapeutics+to+present+MAR001+trial+data+at+AHA+2026/27099157.html <p>Marea Therapeutics, a subsidiary of Lisata Therapeutics (Nasdaq: LSTA), announced that Phase 2b clinical data from its TYDAL study of MAR001 will be presented at the American Heart Association Scientific Sessions 2026, scheduled for November 6–9, 2026, in Chicago, Illinois.</p><p>The presentation, titled "TYDAL-TIMI 78: A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations," is scheduled for Monday, November 9, 2026, at 8:00 a.m. CT, in the late-breaking science session focused on cardiometabolic risk reduction.</p><p>MAR001 is a monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), a protein expressed in adipose tissue. The drug is http://www.streetinsider.com/FDA/Marea+Therapeutics+to+present+MAR001+trial+data+at+AHA+2026/27099157.html Thu, 24 Sep 2026 08:04:08 -0400 LSTA http://www.streetinsider.com/Press+Releases/Marea+Therapeutics%2C+a+Subsidiary+of+Lisata+Therapeutics%2C+Announces+Upcoming+Late-Breaking+Presentation+of+MAR001+Clinical+Data+at+the+American+Heart+Association+Scientific+Sessions+2026/27098976.html <p align="left">SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from the Phase 2b TYDAL study of MAR001, a potential first-in-class monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), will be presented in a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois.</p> <p><em>Presentation details are as http://www.streetinsider.com/Press+Releases/Marea+Therapeutics%2C+a+Subsidiary+of+Lisata+Therapeutics%2C+Announces+Upcoming+Late-Breaking+Presentation+of+MAR001+Clinical+Data+at+the+American+Heart+Association+Scientific+Sessions+2026/27098976.html Thu, 24 Sep 2026 08:00:00 -0400 LSTA